CNS Drugs

, Volume 19, Issue 2, pp 105–123 | Cite as

Neuropsychiatric Adverse Effects of Interferon-α

Recognition and Management
  • Charles L. Raison
  • Marina Demetrashvili
  • Lucile Capuron
  • Andrew H. Miller
Therapy in Practice

Abstract

Recombinant preparations of the cytokine interferon (IFN)-α are increasingly used to treat a number of medical conditions, including chronic viral hepatitis and several malignancies. Although frequently effective, IFNαα induces a variety of neuropsychiatric adverse effects, including an acute confusional state that develops rapidly after initiation of high-dose IFNαα, a depressive syndrome that develops more slowly over weeks to months of treatment, and manic conditions most often characterised by extreme irritability and agitation, but also occasionally by euphoria. Acute IFNαα-induced confusional states are typically characterised by disorientation, lethargy, somnolence, psychomotor retardation, difficulties with speaking and writing, parkinsonism and psychotic symptoms. Strategies for managing delirium should be employed, including treatment of contributing medical conditions, use of either typical or atypical antipsychotic agents and avoidance of medications likely to worsen mental status. Significant depressive symptoms occur in 21–58% of patients receiving IFNαα, with symptoms typically manifesting over the first several months of treatment. The most replicated risk factor for developing depression is the presence of mood and anxiety symptoms prior to treatment. Other potential, but less frequently replicated, risk factors include a past history of major depression, being female and increasing IFNα dosage and treatment duration. The available data support two approaches to the pharmacological management of IFNα-induced depression: antidepressant pretreatment or symptomatic treatment once IFNα has been initiated. Pretreatment might be best reserved for patients already receiving antidepressants or for patients who endorse depression or anxiety symptoms of mild or greater severity prior to therapy. Several recent studies demonstrate that antidepressants effectively treat IFNα-induced depression once it has developed, allowing the vast majority of subjects to complete treatment successfully. Recent data suggest that IFNα-induced depression may be composed of two overlapping syndromes: a depression-specific syndrome characterised by mood, anxiety and cognitive complaints, and a neurovegetative syndrome characterised by fatigue, anorexia, pain and psychomotor slowing. Depression-specific symptoms are highly responsive to serotonergic antidepressants, whereas neurovegetative symptoms are significantly less responsive to these agents. These symptoms may be more effectively treated by agents that modulate catecholaminergic functioning, such as combined serotonin-noradrenaline (norepinephrine) antidepressants, bupropion, psychostimulants or modafinil. Additional factors to consider in selecting an antidepressant include potential drug-drug interactions and adverse effect profile. Finally, IFNα appears capable of inducing manic symptoms. Mania, especially when severe, is a clinical emergency. When this occurs, IFNα and antidepressants should be stopped, an emergency psychiatric consultation should be obtained, and treatment with a mood stabiliser should be initiated.

Notes

Acknowledgements

The authors would like to thank Bobbi J. Woolwine for her support in the preparation of this article. This work was supported in part by the National Institute of Mental Health (MH64619, MH069124 and MH60723) and the Centers for Disease Control and Prevention. Potential conflicts of interest: Charles L. Raison, MD, Speakers’ Bureau for Schering Plough, Wyeth and Eli Lilly; Marina Demetrashvili, no relationships to disclose; Lucile Capuron, no relationships to disclose; Andrew H. Miller, no relationships to disclose.

References

  1. 1.
    Schaefer M, Engelbrecht MA, Gut O, et al. Interferon α (IFNa) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 731–46PubMedCrossRefGoogle Scholar
  2. 2.
    Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon α: a review. Am J Psychiatry 2000; 157(6): 867–76PubMedCrossRefGoogle Scholar
  3. 3.
    Trask P, Esper P, Riba M, et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18(11): 2316–26PubMedGoogle Scholar
  4. 4.
    Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344(13): 961–6PubMedCrossRefGoogle Scholar
  5. 5.
    Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 9(7): 942–7CrossRefGoogle Scholar
  6. 6.
    Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16(6): 1091–9PubMedCrossRefGoogle Scholar
  7. 7.
    Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147(9): 1577–80PubMedCrossRefGoogle Scholar
  8. 8.
    Meyers CA, Obbens EA, Scheibel RS, et al. Neurotoxicity of intraventricularly administered α-interferon for leptomeningeal disease. Cancer 1991; 68(1): 88–92PubMedCrossRefGoogle Scholar
  9. 9.
    Smedley H, Katrak M, Sikora K, et al. Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 1983; 286(6361): 262–4CrossRefGoogle Scholar
  10. 10.
    Rohatiner AZ, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47(3): 419–22PubMedCrossRefGoogle Scholar
  11. 11.
    Niiranen A, Laaksonen R, Iivanainen M, et al. Behavioral assessment of patients treated with α-interferon. Acta Psychiatr Scand 1988; 78(5): 622–6PubMedCrossRefGoogle Scholar
  12. 12.
    Mattson K, Niiranen A, Iivanainen M, et al. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67(10): 958–61PubMedGoogle Scholar
  13. 13.
    Poutiainen E, Hokkanen L, Niemi ML, et al. Reversible cognitive decline during high-dose cc-interferon treatment. Pharmacol Biochem Behav 1994; 47(4): 901–5PubMedCrossRefGoogle Scholar
  14. 14.
    Iivanainen M, Laaksonen R, Niemi ML, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72(5): 475–80PubMedCrossRefGoogle Scholar
  15. 15.
    Farkkila M, Iivanainen M, Roine R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984; 70(1): 42–6PubMedCrossRefGoogle Scholar
  16. 16.
    Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6(4): 355–9PubMedCrossRefGoogle Scholar
  17. 17.
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-α. Neurology 1991; 41(5): 672–6PubMedCrossRefGoogle Scholar
  18. 18.
    Schaefer M, Schwaiger M, Pich M, et al. Neurotransmitter changes by interferon-α and therapeutic implications. Pharmacopsychiatry 2003; 36Suppl. 3: S203–6PubMedGoogle Scholar
  19. 19.
    Blalock JE, Smith EM. Human leukocyte interferon (HuIFNα): potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101(2): 472–8PubMedCrossRefGoogle Scholar
  20. 20.
    Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-a with naltrexone. Cancer Invest 1995; 13(6): 561–6PubMedCrossRefGoogle Scholar
  21. 21.
    Licinio J, Kling MA, Hauser P. Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin Oncol 1998; 25(1 Suppl. 1): 30–8PubMedGoogle Scholar
  22. 22.
    Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004; 29(1): 11–7PubMedGoogle Scholar
  23. 23.
    Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C. Interferon-α inhibits long-term potentiation and unmasks a longterm depression in the rat hippocampus. Brain Res 2000; 885(1): 14–24PubMedCrossRefGoogle Scholar
  24. 24.
    Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43(3): 171–4PubMedCrossRefGoogle Scholar
  25. 25.
    Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153(2): 231–7PubMedGoogle Scholar
  26. 26.
    Hoffman RG, Cohen MA, Alfonso CA, et al. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003; 44(5): 417–20PubMedCrossRefGoogle Scholar
  27. 27.
    Mizoi Y, Kaneko H, Oharazawa A, et al. Parkinsonism in a patient receiving interferon a therapy for chronic hepatitis C [in Japanese]. Rinsho Shinkeigaku 1997; 37(1): 54–6PubMedGoogle Scholar
  28. 28.
    Sarasombath P, Sumida K, Kaku DA. Parkinsonism associated with interferon a therapy for chronic myelogenous leukemia. Hawaii Med J 2002; 61(3): 48, 57PubMedGoogle Scholar
  29. 29.
    Sunami M, Nishikawa T, Yorogi A, et al. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-α. Clin Neuropharmacol 2000; 23(1): 59–61PubMedCrossRefGoogle Scholar
  30. 30.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  31. 31.
    Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5): 643–52PubMedCrossRefGoogle Scholar
  32. 32.
    Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl. 4: 40–55Google Scholar
  33. 33.
    Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321(22): 1501–6PubMedCrossRefGoogle Scholar
  34. 34.
    Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25(3): 283–91PubMedCrossRefGoogle Scholar
  35. 35.
    Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4): 778–89PubMedCrossRefGoogle Scholar
  36. 36.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485–92PubMedCrossRefGoogle Scholar
  37. 37.
    McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet 1987; II(8569): 1175–8CrossRefGoogle Scholar
  38. 38.
    Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24(5): 1034–40PubMedGoogle Scholar
  39. 39.
    Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332(22): 1457–62PubMedCrossRefGoogle Scholar
  40. 40.
    Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1493–9Google Scholar
  41. 41.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958–65PubMedCrossRefGoogle Scholar
  42. 42.
    Fried MW, Shiftman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975–82PubMedCrossRefGoogle Scholar
  43. 43.
    Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37(2): 443–51PubMedCrossRefGoogle Scholar
  44. 44.
    Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-α in patients affected by hepatitis C virus. J Affect Disord 2002; 72(3): 237–41PubMedCrossRefGoogle Scholar
  45. 45.
    Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C [letter]. Am J Psychiatry 1999; 156(7): 1120PubMedGoogle Scholar
  46. 46.
    Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64(6): 708–14PubMedCrossRefGoogle Scholar
  47. 47.
    Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon α-induced depression in chronic hepatitis C patients: comparison between different types of interferon a. Neuropsychobiology 1998; 37(2): 93–7PubMedCrossRefGoogle Scholar
  48. 48.
    Gohier B, Goeb J, Rannou-Dubas K, et al. Hepatitis C, α interferon, anxiety and depression disorders. World J Biol Psychiatry 2003; 4(3): 115–8PubMedCrossRefGoogle Scholar
  49. 49.
    Lang JP, Michel L, Halleguen O. Treatment of affective disorder in hepatitis C: a prospective study in 50 patients. Ann Med Interne (Paris) 2002; 153(7): 22–30Google Scholar
  50. 50.
    Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective study. Gen Hosp Psychiatry 2003; 25(1): 34–8PubMedCrossRefGoogle Scholar
  51. 51.
    Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354(9173): 131–2PubMedCrossRefGoogle Scholar
  52. 52.
    Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002; 20(3–4): 284–8PubMedCrossRefGoogle Scholar
  53. 53.
    Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44(2): 104–12PubMedCrossRefGoogle Scholar
  54. 54.
    Fontana RJ, Schwartz SM, Gebremariam A, et al. Emotional distress during interferon-α-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002; 43(5): 378–85PubMedCrossRefGoogle Scholar
  55. 55.
    Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry 2001; 6(4): 277–94PubMedCrossRefGoogle Scholar
  56. 56.
    Cotler SJ, Wartelle CF, Larson AM, et al. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7(3): 211–7PubMedCrossRefGoogle Scholar
  57. 57.
    Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state [letter]. N Engl J Med 1999; 340(17): 1370PubMedCrossRefGoogle Scholar
  58. 58.
    Van Thiel DH, Friedlander L, De Maria N, et al. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 1998; 45(20): 328–30PubMedGoogle Scholar
  59. 59.
    House JS, Landis KR, Umberson D. Social relationships and health. Science 1988; 241(4865): 540–5PubMedCrossRefGoogle Scholar
  60. 60.
    Capuron L, Ravaud A, Miller AH, et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-α cancer therapy. Brain Behav Immun 2004 May; 18(3): 205–13PubMedCrossRefGoogle Scholar
  61. 61.
    Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003; 160: 1554–65PubMedCrossRefGoogle Scholar
  62. 62.
    Kent S, Bluthe RM, Kelley KW, et al. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13(1): 24–8PubMedCrossRefGoogle Scholar
  63. 63.
    Bluthe RM, Dantzer R, Kelley KW. Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 1992; 573(2): 318–20PubMedCrossRefGoogle Scholar
  64. 64.
    Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection of interferon-α with development of depression during interferon-α therapy. Am J Psychiatry 2003; 160(7): 1342–5PubMedCrossRefGoogle Scholar
  65. 65.
    Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43(4): 425–73PubMedGoogle Scholar
  66. 66.
    Penza KM, Heim C, Nemeroff CB. Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Women Ment Health 2003; 6(1): 15–22CrossRefGoogle Scholar
  67. 67.
    Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20(10): 469–73PubMedCrossRefGoogle Scholar
  68. 68.
    Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000; 48(4): 327–9PubMedCrossRefGoogle Scholar
  69. 69.
    Capuron L, Neurauter G, Musselman DL, et al. Interferon-α-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003 Nov 1; 54(9): 906–14PubMedCrossRefGoogle Scholar
  70. 70.
    Capuron L, Ravaud A, Neveu PJ, et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 5(7): 468–73CrossRefGoogle Scholar
  71. 71.
    Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22(1): 86–90PubMedCrossRefGoogle Scholar
  72. 72.
    Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatrie symptoms during interferon α treatment for chronic hepatitis C. Psychosomatics 2004; 45(1): 49–57PubMedCrossRefGoogle Scholar
  73. 73.
    Schaefer M, Schwaiger M, Berg T. Citalopram for the prevention of interferon-α associated depression in psychiatric risk patients. Hepatology 2003; 38(4 Suppl. 1): 320ACrossRefGoogle Scholar
  74. 74.
    Schafer M, Schmidt F, Amann B, et al. Adding low-dose antidepressants to interferon α treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42Suppl. 1: 43–5PubMedCrossRefGoogle Scholar
  75. 75.
    Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002; 63(2): 166–7PubMedCrossRefGoogle Scholar
  76. 76.
    Gleason OC, Yates WR. Five cases of interferon-α-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40(6): 510–2PubMedCrossRefGoogle Scholar
  77. 77.
    Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63(3): 194–8PubMedCrossRefGoogle Scholar
  78. 78.
    Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993; 88(5): 760–1PubMedGoogle Scholar
  79. 79.
    Schramm TM, Lawford BR, MacDonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173(7): 359–61PubMedGoogle Scholar
  80. 80.
    Yoshida K, Higuchi H, Takahashi H, et al. Favorable effect of milnacipran on depression induced by interferon-α. J Neuropsychiatry Clin Neurosci 2003; 15(2): 242–3PubMedCrossRefGoogle Scholar
  81. 81.
    Janssen HL, Brouwer JT, Van Der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241–3PubMedCrossRefGoogle Scholar
  82. 82.
    Weiss K. Safety profile of interferon-α therapy. Semin Oncol 1998; 25(1 Suppl. 1): 9–13PubMedGoogle Scholar
  83. 83.
    Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32Suppl. 1: 1–21PubMedCrossRefGoogle Scholar
  84. 84.
    Demetrashvili MD, Miller AH, Raison CL. Managing psychiatric side effects of interferon. Proceedings of the 1st Annual Clinical Care Options for Hepatitis Symposium; 2003 Jun 19–22; Laguna Niguel (CA) [online]. Available from URL: http://clinicaloptions.com/hep [Accessed 2004 Nov 15]
  85. 85.
    Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl. 1: 24–32CrossRefGoogle Scholar
  86. 86.
    Gleason OC, Yates WR, Philipsen MA, et al. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004; 45(1): 29–33PubMedCrossRefGoogle Scholar
  87. 87.
    Thase ME. Effects of venlafaxine on blood pressure: a metaanalysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 10(59): 502–8CrossRefGoogle Scholar
  88. 88.
    Ahmed F, Rovner D, Jacobson IM, et al. Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial [abstract]. Hepatology 2003; 38(4 Suppl. 1): 734AGoogle Scholar
  89. 89.
    Weinrieb R, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003; 64: 1502–10PubMedCrossRefGoogle Scholar
  90. 90.
    Edwards IR. Withdrawing drugs: nefazodone, the start of the latest saga. Lancet 2003; 361(9365): 1240PubMedCrossRefGoogle Scholar
  91. 91.
    Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17(4): 638–40PubMedCrossRefGoogle Scholar
  92. 92.
    Nelson JC, Mazure CM, Bowers Jr MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48(4): 303–7PubMedCrossRefGoogle Scholar
  93. 93.
    Debatista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation in partial and non-responders to serotonergic antidepressants. J Psychopharmacol 2003; 23(1): 27–30CrossRefGoogle Scholar
  94. 94.
    Tran PV, Bymaster FP, Mcnamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23(1): 78–86PubMedCrossRefGoogle Scholar
  95. 95.
    Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326(19): 1250–6PubMedCrossRefGoogle Scholar
  96. 96.
    Goodnick PJ. Treatment of chronic fatigue syndrome with venlafaxine [letter]. Am J Psychiatry 1996; 153(2): 294PubMedGoogle Scholar
  97. 97.
    Goodnick PJ. Bupropion in chronic fatigue syndrome [letter]. Am J Psychiatry 1990; 147(8): 1091PubMedGoogle Scholar
  98. 98.
    Goodnick PJ, Sandoval R, Brickman A, et al. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992; 32(9): 834–8PubMedCrossRefGoogle Scholar
  99. 99.
    Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum Online 2002; 29(7): E85–90CrossRefGoogle Scholar
  100. 100.
    Sugawara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16(3): 261–3PubMedCrossRefGoogle Scholar
  101. 101.
    Sarhill N, Walsh D, Nelson KA, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18(3): 187–92PubMedCrossRefGoogle Scholar
  102. 102.
    Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002; 249(8): 983–7PubMedCrossRefGoogle Scholar
  103. 103.
    Afdhal NH, Klopfer A, Tang L, et al. Hemoglobin increase is independently associated with increased health-related quality of life (HRQL) in anemic interferon/ribavirin (IFN/RBV)-treated hepatitis C virus (HCV)-infected patients treated with epoetin alfa. Hepatology 2003; 38(4 Suppl. 1): 312ACrossRefGoogle Scholar
  104. 104.
    Afdhal NH, Goon B, Smith K, et al. Epoetin alfa (EPO) improves and maintains health-related quality of life (HRQL) in anemic HCV-infected patients receiving interferon/ribavirin (IFN/RBV): HRQL results from the proactive study. Hepatology 2003; 38(4 Suppl. 1): 302ACrossRefGoogle Scholar
  105. 105.
    Altindag A, Ozbulut O, Ozen S, et al. Interferon-α-induced mood disorder with manic features. Gen Hosp Psychiatry 2001; 23(3): 168–70PubMedCrossRefGoogle Scholar
  106. 106.
    Carpiniello B, Orru MG, Baita A, et al. Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 1998; 55(1): 88–9PubMedCrossRefGoogle Scholar
  107. 107.
    Kanno A, Yamada M, Abe M, et al. A case of interferon α induced manic psychosis in chronic hepatitis C. Tohoku J Exp Med 1999; 187(1): 79–82PubMedCrossRefGoogle Scholar
  108. 108.
    Monji A, Yoshida I, Tashiro K, et al. A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C. Psychosomatics 1998; 39(6): 562–4PubMedCrossRefGoogle Scholar
  109. 109.
    Strite D, Valentine AD, Meyers CA. Manic episodes in two patients treated with interferon α. J Neuropsychiatry Clin Neurosci 1997; 9(2): 273–6PubMedGoogle Scholar
  110. 110.
    Onyike CU, Bonner JO, Lyketsos CG, et al. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 61(3): 429–35CrossRefGoogle Scholar
  111. 111.
    Castera L, Constant A, Henry C, et al. Incidence, risk factors and treatment of mood disorders associated with peginterferon and ribavirin therapy in patients with chronic hepatitis C: results of a prospective study [abstract]. Hepatology 2003; 38(4 Suppl. 1): 735ACrossRefGoogle Scholar
  112. 112.
    Gould RA, Ball S, Kaspi SP, et al. Prevalence and correlates of anger attacks: a two site study. J Affect Disord 1996; 39(1): 31–8PubMedCrossRefGoogle Scholar
  113. 113.
    Appels A. Why do imminent victims of a cardiac event feel so tired? Int J Clin Pract 1997; 51(7): 447–50PubMedGoogle Scholar
  114. 114.
    Altshuler LL, Post RM, Leverich GS, et al. Antidepressantinduced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152(8): 1130–8PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Charles L. Raison
    • 1
  • Marina Demetrashvili
    • 1
  • Lucile Capuron
    • 1
  • Andrew H. Miller
    • 1
  1. 1.Department of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlantaUSA

Personalised recommendations